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ORIGINAL ARTICLE
Endobronchial Palliation Using Nd:YAG Laser Is Associated
with Improved Survival when Combined with Multimodal
Adjuvant Treatments
Charles C. Han, MBBS,* Davin Prasetyo, BMedSc,† and Gavin M. Wright, MBBS, FRACS*
Background: Endobronchial neodymium:yttrium aluminum garnet
(Nd:YAG) laser therapy has been shown to be safe and effective in
palliating large airway malignancies. The role of multimodal therapy
with stenting, brachytherapy, chemotherapy, and radiotherapy to-
gether with Nd:YAG laser therapy is unclear.
Aim: This study aims to confirm the safety and effectiveness of
Nd:YAG laser therapy in the contemporary setting and to investigate
the effectiveness of multimodal therapy compared with laser alone.
Methods: One hundred fifty-three Nd:YAG laser treatments on 110
patients between 1999 and 2004 were reviewed retrospectively.
Symptom scores for dyspnoea, hemoptysis, and cough before and
after the procedure were compared. Survival and time to reinterven-
tion were analyzed using the Kaplan–Meier method. Multimodality
treatment was compared with Nd:YAG laser therapy alone to
determine differences in survival and time to reintervention. p values
less than 0.05 were considered significant.
Results: There were no operative mortalities directly caused by
laser intervention, although 30-day mortality was 6.5%. Deaths were
attributable to progression of advanced neoplastic processes rather
than laser intervention, and 6.5% of patients had some postoperative
morbidity. After Nd:YAG laser intervention, 76% of patients re-
ported improvement to dyspnoea, 94% for hemoptysis, and 75% for
cough. Median survival after Nd:YAG laser treatment was 6.64
months; 21% of patients required repeated laser treatment. Com-
pared with Nd:YAG laser treatment alone, multimodality treatments
significantly prolonged median time to reintervention by 1.7 months
(p  0.002) and prolonged median survival by 4.9 months (p 
0.001) in patients with NSCLC.
Conclusion: Nd:YAG laser intervention is safe and effective for
palliation of endobronchial malignancies. In most cases, it only
needs to be performed once. Compared with Nd:YAG laser therapy
alone, multimodal treatment prolonged survival.
Key Words: Lung cancer, Nd:YAG laser, Palliation, Radiotherapy,
Brachytherapy, Multi-modal therapy.
(J Thorac Oncol. 2007;2: 59–64)
Endobronchial malignancy is a common problem in non-small cell lung cancer (NSCLC), small cell lung cancer,
and a range of tumors that metastasize from elsewhere in the
body. In NSCLC, it is a loco-regional mechanism of mortality
and poor performance status, even in patients without distant
metastases. The common symptoms of endobronchial malig-
nancy (cough, hemoptysis, and dyspnoea) are distressing and
debilitating. An endobronchial cause should always be
sought, because these often can be reversed or improved
with interventions such as laser ablation, stenting, brachy-
therapy, external beam radiotherapy, or chemotherapy.
The use of the neodymium:yttrium aluminum garnet (Nd:
YAG) laser and its results are retrospectively studied in
this paper.
Dumon et al.1 first employed Nd:YAG laser surgery for
bronchogenic lung cancer in 1982. Since then, many centers
have employed this tool to palliate obstruction, bleeding, and
symptomatic dyspnoea secondary to locally advanced lung
cancers and endobronchial metastases from other malignan-
cies. Nd:YAG laser surgery reliably allows the immediate
coagulation and resection of endobronchial lesions and relief
of obstruction. For this purpose, it is superior to conventional
radiotherapy or chemotherapy.
Several studies have reported on the safety and effec-
tiveness of Nd:YAG laser therapy2–6 using data from more
than 10 years ago. Two centers7,8 have reported their expe-
rience in Australia; these were small studies performed dur-
ing the initial evaluation phases of Nd:YAG laser therapy, the
latest one being from 1990. The purpose of this article is to
report on the contemporary experience of Nd:YAG laser
surgery for the treatment of endobronchial lesions. Because
laser is usually a palliative procedure involving incomplete
removal of tumor, it is important to determine its duration of
relief and to confirm its safety and efficacy in our practice. In
addition, patients thought to be at high risk for recurrence of
endobronchial disease were offered additional therapy such
as stenting, brachytherapy chemotherapy, or radiotherapy. If
these additional therapies had any effect, we would expect the
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survival and time to reintervention with laser to be the same
or better in this group.
METHODS
In the period between January 1, 1999 and September
1, 2004, all patients who received Nd:YAG laser treatment
for malignant tracheobronchial lesions at the St. Vincent’s
Hospital, St. Vincent’s & Mercy’s Private Hospital and the
Peter MacCallum Cancer Institute in Melbourne, Australia
were included in the study. These closely approximated
facilities have formed a multidisciplinary lung cancer alli-
ance, especially for thoracic surgical services. All patients
were referred for palliation of symptoms related to tracheo-
bronchial lesions.
Procedures were performed under general anesthesia
using a rigid bronchoscope and/or fiberoptic bronchoscope.
The procedures were performed by two qualified thoracic
surgeons using the same technique. The flexible scope was
either passed via an endotracheal tube or through the rigid
bronchoscope for bronchial toilet and to direct the laser beam.
The rigid bronchoscope could be used to core out or debulk
larger tumors. Laser treatments were delivered using a Nd:
YAG laser. A series of pulses between 0.5 and 1.0 second
were used, with a power setting of 12 to 30 watts. Most
patients were ventilated intermittently by a Sanders jet insuf-
flator applied to the bronchoscope. This allowed entrainment
of air, resulting in a low effective inspired oxygen concen-
tration. For patients who were ventilated through a closed
system and endobronchial tube, inspired oxygen concentra-
tions were kept at 30% if possible. The pulsed mode and low
inspired oxygen concentrations were chosen to minimize the
risk of unintentional penetrating injury or airway fire, while
being sufficient to vaporize or coagulate tissue. Patients
usually were discharged on the day of surgery, except when
immediate postoperative complications occurred. Some un-
well patients with advanced disease were inpatients at the
time of the procedure.
Data were collected by systematic review of all elec-
tronic and paper medical histories of patients who received
laser surgery at the aforementioned institutes. The data were
recorded on a proforma datasheet. Patients with insufficient
data sets were excluded from the relevant analysis. Symp-
toms of hemoptysis, dyspnoea, and cough were noted from
the patient histories. Dyspnoea was scored as mild, moderate,
or severe based on the doctors’ assessment and, where avail-
able, the documented patient activity level. Mild dyspnoea
was shortness of breath on exertion, moderate dyspnoea was
shortness of breath during minor activity, and severe dys-
pnoea was shortness of breath at rest.
Data were entered into Microsoft Excel X. Statistical
analysis was performed using SPSS version 11.0.2.
For the patient population involved, their survival did
not follow a normal distribution. Thus, medians were used to
estimate any central tendency, and nonparametric methods
were used for statistical analysis. The Kolmogorov–Smirnov
test is a nonparametric test used to compare survival in two
independent samples of patients. Asymptotic p values less
than 0.05 were considered significant. Kaplan–Meier plots
were used for analysis of survival; patients were censored if
the endpoint was not reached.
All patients were included for the analysis of laser
complications. Only patients with malignant disease requir-
ing palliation were included for analysis of survival and
disease-free survival. Two patients who were treated for
carcinoid disease were excluded.
RESULTS
One hundred ten patients who received 153 Nd:YAG
laser treatments for tracheobronchial lesions during the
5-year period were included in the study. Sixty-two patients
were excluded from the study because of inadequate fol-
low-up or incomplete documentation that made data analysis
impossible. The age of the patient group ranged from 33 to
87, with a mean of 67 years. Seventy-eight (71%) of the
patients were male.
Eighty-seven patients received one laser treatment
only. Twenty-three patients received multiple treatments,
accounting for 66 laser interventions in total, with one patient
receiving nine treatments. The mean number of treatments
each patient received was 1.39. Of the lesions treated, 80
(73%) were NSCLCs, and 20 (18%) were metastatic lesions
from colon (eight), sarcoma (three), breast (two), melanoma
(two), kidney (two), prostate, thyroid, or nasopharyngeal
SCC. Other pathologies included small cell lung cancers
(four), primary sarcoma (two), carcinoid (two), plasmacy-
toma, and local invasion from esophageal cancer (Table 1).
These patients were further divided into two groups.
Group 1 received single-modality treatment with Nd:YAG
laser surgery only. Group 2 received multimodality treatment
with chemotherapy, radiotherapy, brachytherapy, or stenting
in conjunction with Nd:YAG laser surgery (Table 2). The
pathology between the two groups was slightly different. The
single-modality group contained more patients with benign
pathology and stage 3B NSCLC, and the multimodal group
TABLE 1. Range of Pathology and Staging of Non-Small
Cell Lung Cancer (NSCLC) Cases
Lesion Type No. (%)
Primary malignancy
NSCLC 80 (73%)
Squamous cell 50 (45%)
Adenocarcinoma 17 (15%)
Large cell 4 (4%)
Unknown 9 (11%)
Small cell lung cancer 4 (3.5%)
Sarcoma 2 (2%)
Secondary malignancy 20 (18%)
Other 4 (3.5%)
Staging of NSCLC
IB 4%
II 2%
III 52%
IV 22%
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contained more patients with metastatic NSCLC (Table 3).
The two groups were compared for survival differences.
Symptom Palliation
In this study, the symptoms of dyspnoea, cough, and
hemoptysis were the main indications for endobronchial laser
surgery (Figure 1). These three specific parameters were
evaluated to assess the degree of improvement after endo-
bronchial surgery.
Dyspnoea was a symptom before 130 laser treatments.
After laser surgery, 71 (55%) of patients reported complete
resolution of dyspnoea; 31 (24%) patients did not notice any
improvement to dyspnoea, although 17 (13%) of these pa-
tients had had only mild dyspnoea before treatment. Of the
remainder, 16 (12%) patients reported moderate improve-
ment, and 12 (9%) patients reported mild improvement. Of
the patients who had moderate or severe dyspnoea before
treatment, 51 of 93 (55%) had complete relief of dyspnoea,
14 of 93 (15%) had no relief, 22 of 93 (24%) had moderate
relief, and six of 93 (6%) had mild relief.
Hemoptysis was present in 52 cases before laser sur-
gery. After treatment, 40 (77%) patients were free of hemop-
tysis, nine (17%) reported subjective improvement of hemop-
tysis, and three (6%) had no improvement of hemoptysis.
Cough was present in 97 patients before laser surgery.
After treatment, 41 (42%) patients reported no further cough,
32 (33%) patients reported improvement to cough, and 24
(25%) patients did not have any improvement to cough.
Complications
There were no operative mortalities directly caused by
laser intervention. Nevertheless, 10 patients out of 153 treat-
ments died in the 30-day period after intervention. All of
these patients were discharged from hospital and then died
more than 15 days after intervention. Eight of these patients
had metastatic disease, and two had T4 NSCLC. They died
from progression of neoplastic processes rather than compli-
cations directed caused by laser intervention. Other compli-
cations occurred in 10 of 153 (6.5%) laser treatments. In four
patients, endobronchial bleeding prolonged hospital stay.
Other complications included rapid AF, pneumonia, myalgia
(2), hypoxia, and acute exacerbation of chronic obstructive
airways disease.
Survival and Time to Reintervention
Survival of 108 patients with malignant endobronchial
disease after their first laser intervention is represented on a
Kaplan–Meier curve in Figure 2. Patients with carcinoid
disease and benign strictures were excluded from the analy-
sis. Patients were censored at the study closure date if they
were still alive. Ten patients were known to still be alive at
the study closure date. The median survival was 6.64  1.02
months.
Of 151 laser interventions for malignant endobronchial
disease, time to reintervention with laser surgery was plotted
on a Kaplan–Meier curve (Figure 3). Patients were censored
at time of death or study closure date (if still alive). The
median time to reintervention was 22.1 months. In the group
of patients who had multiple laser reinterventions, the median
time to reintervention calculated using the same method was
4.2 months.
Effect of Cancer Staging on Time to
Reintervention
The effect of cancer stage on the length of time to
reintervention was also investigated statistically in patients
TABLE 2. Summary Adjunctive Treatments Used in
Combination with Each Laser Treatment
Number of Treatments
Adjunct treatment modalities
Brachytherapy 17
Chemotherapy 7
Radiotherapy 50
Stenting 4
Chemoradiotherapy 12
Total 90
No adjunctive treatment used 53
TABLE 3. Summary of Differences in Pathology between
Patients Treated with Single-Modality and Multimodality
Therapy
Single Modality
(36 patients)
Multimodality
(74 patients)
Non-small cell lung cancer 25 (69%) 55 (74%)
IV 4 (11%) 17 (23%)
IIIb 14 (39%) 20 (27%)
IIIa 7 (19%) 18 (24%)
Metastasis 7 (18%) 13 (18%)
Small cell lung cancer 0 4 (5%)
Sarcoma 0 2 (3%)
Other 4 (19%) 0
Time of death unknown/still living 5 (14%) 9 (12%)
FIGURE 1. Venn diagram representing indications for laser
treatment.
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who had had multiple laser interventions. Patients with can-
cer staging less than 3A was compared with patients with
cancer staging 3B or 4, the differences in time to reinterven-
tion between these two groups were not statistically signifi-
cant. In the patients with cancer staging less than 3A, open
operative surgery was not possible because they were poor
surgical candidates.
Single- versus Multimodality Therapy
There were 96 patients with malignant lung disease,
primary or metastatic, who had documented date of death. Of
these patients, 30 received single-modality laser intervention
and 66 received multimodality treatment. Median length of
survival from the first laser intervention was longer in pa-
tients who received multimodal treatment (6.99 versus 3.79
mo). This was found to be statistically significant using the
Kolmogorov–Smirnov test (p  0.002) (Table 4).
There were 72 patients with NSCLC who had docu-
mented date of death. Twenty-one received single-modality
laser intervention, and 51 received multimodality treatment.
Median length of survival from the first laser intervention was
longer in patients who received multimodality treatment
(7.17 versus 2.27 mo). This was found to be significant using
the Kolmogorov–Smirnov test (p  0.001) (Table 4).
In 23 patients who had multiple laser interventions, the
length of time to reintervention after single-modality laser
intervention alone was compared with the length of time to
reintervention after multimodal treatment. Of the 66 treat-
ments, 37 were single modality and 29 were multimodality.
Median time to reintervention in patients who received mul-
timodal treatment in addition to laser treatment (3.9 mo) was
significantly longer than that for patients who received laser
treatment alone (median 2.2 mo) This was found to be
statistically significant using the Kolmogorov–Smirnov test
(p  0.006).
DISCUSSION
When malignant bronchial obstruction proves unresect-
able for medical, physiological, or anatomic reasons, pallia-
tion, with the aim to improve quality of life and, if possible,
prolong life, is the main objective for patient management.
Chemotherapy and external beam radiotherapy have been the
main forms of treatment for primary and secondary cancers of
the lung. In recent times, endobronchial therapy including
Nd:YAG laser therapy, photodynamic therapy, and brachy-
therapy have been shown in several studies2–8 to be highly
effective for palliation of symptoms caused by malignant
lesions involving the major airways of the endobronchial tree.
Using the Nd:YAG laser to recanalize narrowed or occluded
bronchi and coagulating bleeding surfaces can rapidly accom-
plish symptom palliation.
The 30-day mortality in our group of patients was
6.5%. This is a result of the poor health of the patients on
FIGURE 2. Kaplan–Meier curve of all-cause mortality for all
patients.
FIGURE 3. Kaplan–Meier curve for time to
reintervention. Patients were censored at death
and study close-out date.
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whom we performed laser interventions, rather than of com-
plications directly associated with the intervention. The 10
patients were all discharged from the hospital and died
between 15 and 30 days after treatment. This is not surprising
given the palliative nature of the treatment.
The results of this study confirm the effectiveness of
Nd:YAG laser therapy reported by previous studies. Cava-
liere et al.,2 in a large review of 2008 patients, found that 93%
benefitted from laser therapy; this is similar to our results.
Our study is unique in that we looked at the effectiveness of
laser treatment in palliating a range of symptoms. Other
studies in the literature have focused mainly on laser treat-
ment’s effects on dyspnoea. We have found that laser therapy
is most effective at palliating hemoptysis, with 94% receiving
some benefit and 77% free of hemoptysis. It is also very
effective in palliating dyspnoea; most people (76%) received
some benefit, with 55% of patients rendered asymptomatic.
Patients who did not receive relief may have had underlying
lung disease related to smoking or lung damage caused by
neoplasia. Palliation of cough was less successful, but most
patients had some benefit.
The median survival in our patients after laser therapy
is 6.6 months. This certainly suggests that palliation of
symptomatic patients would be of benefit, because their life
expectancy is still substantial. An early study by Unger9
compared lung cancer patients treated with laser therapy
against a control group; this demonstrated a substantial sur-
vival advantage, with patients treated with laser therapy
surviving twice as long (mean of 400 versus 200 days) as the
patients who did not receive laser therapy. Such a study
would not be possible today. The median for time to reinter-
vention was 22.1 months in our study. This may represent a
statistical anomaly because of the high number of censored
patients who died after receiving one laser treatment in our
study. Brutinel et al.5 were the only other group who reported
on time to reintervention, which was 4.3 months in their
study. This group used death as an extra endpoint. Nonethe-
less, in all studies reviewed,2–8 most patients received only
one laser treatment before death. We extrapolate that the
palliative effect of laser surgery is maintained until patient
death from progression of native disease in the majority of cases.
In our patient group, patients who received multimodal
therapy demonstrated significantly prolonged survival, com-
pared with those receiving laser surgery alone, both for
NSCLC and lung malignancies in general. Median survival
was approximately 5 months longer in the group of patients
who received additional treatments along with laser surgery.
Multimodal therapy also lengthened the time to reinterven-
tion in the group of patients that required multiple laser
interventions. In the group of patients who required multiple
laser interventions, there was a disproportionately larger
percentage who received single-modality treatment only.
Thirty-seven of 66 treatments were single modality; this may
explain why some patients in this group required more than
one laser treatment. These finding are further strengthened by
the fact that most patients who received multimodal therapy
were stratified by higher-risk tumors at the onset of treatment,
which presumably would have resulted in reduced survival.
Several other studies have found that multimodal therapy,
especially in combination with brachytherapy, did signifi-
cantly improve survival time. Santos et al.10 found that
multimodality therapy significantly improved the 3-year cu-
mulative survival, and Shea et al.11 found that Nd:YAG and
brachytherapy significantly improved survival compared with
laser therapy alone. These studies only involved small patient
numbers, but these results are encouraging. Although Miller
et al.12 did not find statistically significant improved survival
in patients who received brachytherapy and laser therapy
compared with laser therapy alone, patients who received
combination therapy did have improved survival at 6 months.
Many experts are now advocating a multimodal ap-
proach, especially in combining laser therapy with brachy-
therapy. Although our study clearly indicates that multimodal
interventions prolong survival compared with laser interven-
tion alone, this is limited by the retrospective nature of the
study. Whether laser therapy in combination with brachyther-
apy indeed improves survival compared with laser therapy
alone has not been proven beyond doubt. An additional large
prospective trial would be useful in clarifying an evidence-
based approach for this problem. Meanwhile, our study con-
firms Nd:YAG laser treatment as safe and highly effective for
palliation of symptoms of malignant endobronchial obstruc-
tion and offers further compelling evidence supporting the
multimodality treatment of lung malignancies.
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